Work

FRACTION (Fast Real-time Assessment of Combination Therapies in Immuno-Oncology)-gastric cancer (GC): A randomized, open-label, adaptive, phase 2 study of nivolumab in combination with other immuno-oncology (IO) agents in patients with advanced GC.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.tps4137

Authors: Praveen Aanur, Martin Gutierrez, Ronan Joseph Kelly, Jaffer A. Ajani, Geoffrey Yuyat Ku, Crystal Shereen Denlinger, Thomas J. George, Megan Wind-Rotolo, Xiaowei Guan, Manish Gupta, Timothy P. Reilly, Paula M. Fracasso

Institutions: Bristol-Myers Squibb (United States), Hackensack University Medical Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Fox Chase Cancer Center, UF Health Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891999356

Cites:

Cited by: 16

Related to: 10